{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:14:22Z","timestamp":1792088062162,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T00:00:00Z","timestamp":1457568000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"SGH Research Fund","award":["SRG\/C3\/03\/2014"],"award-info":[{"award-number":["SRG\/C3\/03\/2014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00262-016-1815-8","type":"journal-article","created":{"date-parts":[[2016,3,10]],"date-time":"2016-03-10T08:08:19Z","timestamp":1457597299000},"page":"525-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts"],"prefix":"10.1007","volume":"65","author":[{"given":"Su Li","family":"Poh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8098-2590","authenticated-orcid":false,"given":"Yeh Ching","family":"Linn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,3,10]]},"reference":[{"issue":"1","key":"1815_CR1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2141.2002.03247.x","volume":"116","author":"YC Linn","year":"2002","unstructured":"Linn YC, Lau LC, Hui KM (2002) Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol 116(1):78\u201386","journal-title":"Br J Haematol"},{"issue":"9","key":"1815_CR2","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1182\/blood.V92.9.3318","volume":"92","author":"C Hoyle","year":"1998","unstructured":"Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS (1998) Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92(9):3318\u20133327","journal-title":"Blood"},{"issue":"6","key":"1815_CR3","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/ijc.21994","volume":"119","author":"M Kornacker","year":"2006","unstructured":"Kornacker M, Moldenhauer G, Herbst M, Weilguni E, Tita-Nwa F, Harter C, Hensel M, Ho AD (2006) Cytokine-induced killer cells against autologous CLL: direct cytotoxic effects and induction of immune accessory molecules by interferon-\u03b3. Int J Cancer 119(6):1377\u20131382","journal-title":"Int J Cancer"},{"issue":"5","key":"1815_CR4","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1517\/14712598.2012.668879","volume":"12","author":"S Thanendrarajan","year":"2012","unstructured":"Thanendrarajan S, Kim Y, Schmidt-Wolf I (2012) New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther 12(5):565\u2013572","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"1815_CR5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/14712598.2012.675323","volume":"12","author":"G Mesiano","year":"2012","unstructured":"Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Diego LG, Carnevale-Schianca F, Fagioli F, Piacibello W, Aglietta M, Sangiolo D (2012) Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin Biol Ther 12(6):673\u2013684","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"1815_CR6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL (1991) Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174(1):139\u2013149","journal-title":"J Exp Med"},{"issue":"suppl 1","key":"1815_CR7","first-page":"S47","volume":"92","author":"YC Linn","year":"2013","unstructured":"Linn YC (2013) Cytokine-induced killer cells for leukemia\u2014from bench to bedside. Ann Hematol 92(suppl 1):S47","journal-title":"Ann Hematol"},{"key":"1815_CR8","doi-asserted-by":"crossref","first-page":"897214","DOI":"10.1155\/2014\/897214","volume":"2014","author":"CE J\u00e4kel","year":"2014","unstructured":"J\u00e4kel CE, Vogt A, Gonzalez-Carmona MA, Schmidt-Wolf IGH (2014) Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res 2014:897214","journal-title":"J Immunol Res"},{"issue":"1","key":"1815_CR9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3109\/14653249.2011.613931","volume":"14","author":"E Rettinger","year":"2012","unstructured":"Rettinger E, Ku\u00e7i S, Naumann I, Becker P, Kreyenberg H, Anzaghe M, Willasch A, Koehl U, Bug G, Ruthardt M, Klingebiel T, Fulda S, Bader P (2012) The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 14(1):91\u2013103","journal-title":"Cytotherapy"},{"issue":"10","key":"1815_CR10","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3109\/14653249.2012.714864","volume":"14","author":"L Durrieu","year":"2012","unstructured":"Durrieu L, Gregoire-Gauthier J, Dieng MM, Fontaine F, le Deist F, Haddad E (2012) Human interferon-alpha increases the cytotoxic effect of CD56(+) cord blood-derived cytokine-induced killer cells on human B-acute lymphoblastic leukemia cell lines. Cytotherapy 14(10):1245\u20131257","journal-title":"Cytotherapy"},{"issue":"12","key":"1815_CR11","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3324\/haematol.2010.026310","volume":"95","author":"V Marin","year":"2010","unstructured":"Marin V, Pizzitola I, Agostoni V, Attianese GMPG, Finney H, Lawson A, Pule M, Rousseau R, Biondi A, Biagi E (2010) Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 95(12):2144\u20132152","journal-title":"Haematologica"},{"key":"1815_CR12","doi-asserted-by":"crossref","first-page":"238924","DOI":"10.1155\/2012\/238924","volume":"2012","author":"C Schlimper","year":"2012","unstructured":"Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IGH (2012) Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol 2012:238924","journal-title":"Clin Dev Immunol"},{"issue":"8","key":"1815_CR13","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1038\/bjc.2014.140","volume":"110","author":"Y Zou","year":"2014","unstructured":"Zou Y, Li F, Hou W, Sampath P, Zhang Y, Thorne SH (2014) Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells. Br J Cancer 110(8):1992\u20131999","journal-title":"Br J Cancer"},{"issue":"10","key":"1815_CR14","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1158\/1078-0432.CCR-07-4079","volume":"14","author":"R Berger","year":"2008","unstructured":"Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, Leiba M, Koren-Michowitz M, Shimoni A, Nagler A (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14(10):3044\u20133051","journal-title":"Clin Cancer Res"},{"issue":"33","key":"1815_CR15","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","volume":"31","author":"P Armand","year":"2013","unstructured":"Armand P, Nagler A, Weller EA, Devine SM, Avigan DE, Chen YB, Kaminski MS, Holland HK, Winter JN, Mason JR, Fay JW, Rizzieri DA, Hosing CM, Ball ED, Uberti JP, Lazarus HM, Mapara MY, Gregory SA, Timmerman JM, Andorsky D et al (2013) Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 31(33):4199\u20134206","journal-title":"J Clin Oncol"},{"issue":"4","key":"1815_CR16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372(4):311\u2013319","journal-title":"N Engl J Med"},{"issue":"22","key":"1815_CR17","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1182\/blood-2012-06-437558","volume":"120","author":"N Vey","year":"2012","unstructured":"Vey N, Bourhis JH, Boissel N, Bordessoule D, Prebet T, Charbonnier A, Etienne A, Andre P, Romagne F, Benson D, Dombret H, Olive D (2012) A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission. Blood 120(22):4317\u20134323","journal-title":"Blood"},{"issue":"22","key":"1815_CR18","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1182\/blood-2012-06-438028","volume":"120","author":"DM Benson","year":"2012","unstructured":"Benson DM, Hofmeister CC, Padmanabhan S, Suvannasankha A, Jagannath S, Abonour R, Bakan C, Andre P, Efebera Y, Tiollier J, Caligiuri MA, Farag SS (2012) A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed\/refractory multiple myeloma. Blood 120(22):4324\u20134333","journal-title":"Blood"},{"issue":"4","key":"1815_CR19","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1053\/bbmt.2001.v7.pm11349808","volume":"7","author":"JC Alvarnas","year":"2001","unstructured":"Alvarnas JC, Linn YC, Hope EG, Negrin RS (2001) Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 7(4):216\u2013222","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"1815_CR20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1365-2567.2008.02910.x","volume":"126","author":"YC Linn","year":"2009","unstructured":"Linn YC, Lau SKJ, Liu BH, Ng LH, Yong HX, Hui KM (2009) Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 126(3):423\u2013435","journal-title":"Immunology"},{"issue":"5","key":"1815_CR21","doi-asserted-by":"crossref","first-page":"616.e2","DOI":"10.1016\/j.exphem.2009.01.010","volume":"37","author":"M Franceschetti","year":"2009","unstructured":"Franceschetti M, Pievani A, Borleri G, Vago L, Fleischhauer K, Golay J, Introna M (2009) Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 37(5):616.e2\u2013628.e2","journal-title":"Exp Hematol"},{"issue":"6","key":"1815_CR22","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.exphem.2005.03.005","volume":"33","author":"YC Linn","year":"2005","unstructured":"Linn YC, Wang SM, Hui KM (2005) Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays. Exp Hematol 33(6):671\u2013681","journal-title":"Exp Hematol"},{"issue":"12","key":"1815_CR23","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V76.12.2599.2599","volume":"76","author":"XG Zhang","year":"1990","unstructured":"Zhang XG, Bataille R, Jourdan M, Saeland S, Banchereau J, Mannoni P, Klein B (1990) Granulocyte-macrophage colony-stimulating factor synergizes with interleukin-6 in supporting the proliferation of human myeloma cells. Blood 76(12):2599\u20132605","journal-title":"Blood"},{"key":"1815_CR24","author":"WC Chan","year":"2014","unstructured":"Chan WC, Linn YC (2014) A comparison between cytokine- and bead-stimulated polyclonal T cells: the superiority of each and their possible complementary role. Cytotechnology. doi: 10.1007\/s10616-014-9825-x","journal-title":"Cytotechnology"},{"key":"1815_CR25","doi-asserted-by":"crossref","unstructured":"Grosso J, Horak CE, Inzunza D, Cardona DM, Simon JS, Gupta AK, Sankar V, Park JS, Kollia G, Taube JM, Anders R, Jure-Kunkel M, Novotny JJ, Taylor CR, Zhang X, Phillips T, Simmons P, Cogswell J (2013) Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538). J Clin Oncol 31 (suppl; abstr 3016)","DOI":"10.1200\/jco.2013.31.15_suppl.3016"},{"issue":"16","key":"1815_CR26","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-04-2672","volume":"11","author":"H Tamura","year":"2005","unstructured":"Tamura H, Dan K, Tamada K, Nakamura K, Shioi Y, Hyodo H, Wang SD, Dong H, Chen L, Ogata K (2005) Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res 11(16):5708\u20135717","journal-title":"Clin Cancer Res"},{"issue":"9","key":"1815_CR27","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1002\/eji.200939274","volume":"39","author":"WD Hastings","year":"2009","unstructured":"Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC, Zheng XX, Strom TB, Hafler DA, Kuchroo VK (2009) TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines. Eur J Immunol 39(9):2492\u20132501","journal-title":"Eur J Immunol"},{"issue":"5","key":"1815_CR28","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1158\/2326-6066.CIR-14-0039","volume":"2","author":"AC Anderson","year":"2014","unstructured":"Anderson AC (2014) Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2(5):393\u2013398","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"1815_CR29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1517\/14712598.2011.540563","volume":"15","author":"S Sierro","year":"2011","unstructured":"Sierro S, Romero P, Speiser DE (2011) The CD4-like molecule LAG-3, biology and therapeutic applications. Expert Opin Ther Targets 15(1):91\u2013101","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"1815_CR30","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/sj.leu.2402103","volume":"15","author":"MP Velders","year":"2001","unstructured":"Velders MP, ter Horst SA, Kast WM (2001) Prospect for immunotherapy of acute lymphoblastic leukemia. Leukemia 15(5):701\u2013706","journal-title":"Leukemia"},{"issue":"11","key":"1815_CR31","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1182\/blood.V97.11.3574","volume":"97","author":"MR Baer","year":"2001","unstructured":"Baer MR, Stewart CC, Dodge RK, Leget G, Sul\u00e9 N, Mr\u00f3zek K, Schiffer CA, Powell BL, Kolitz JE, Moore JO, Stone RM, Davey FR, Carroll AJ, Larson RA, Bloomfield CD (2001) High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood 97(11):3574\u20133580","journal-title":"Blood"},{"issue":"3","key":"1815_CR32","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2567.2010.03337.x","volume":"131","author":"J Bergen van","year":"2010","unstructured":"van Bergen J, Koning F (2010) The tortoise and the hare: slowly evolving T-cell responses take hastily evolving KIR. Immunology 131(3):301\u2013309","journal-title":"Immunology"},{"issue":"6","key":"1815_CR33","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2012-11-464685","volume":"122","author":"J Gertner-Dardenne","year":"2013","unstructured":"Gertner-Dardenne J, Fauriat C, Orlanducci F, Thibult ML, Pastor S, Fitzgibbon J, Bouabdallah R, Xerri L, Olive D (2013) The co-receptor BTLA negatively regulates human V\u03b39V\u03b42 T-cell proliferation: a potential way of immune escape for lymphoma cells. Blood 122(6):922\u2013931","journal-title":"Blood"},{"issue":"4","key":"1815_CR34","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1158\/0008-5472.CAN-11-2637","volume":"72","author":"J Fourcade","year":"2012","unstructured":"Fourcade J, Sun Z, Pagliano O, Guillaume P, Luescher IF, Sander C, Kirkwood JM, Olive D, Kuchroo V, Zarour HM (2012) CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 72(4):887\u2013896","journal-title":"Cancer Res"},{"issue":"10","key":"1815_CR35","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.4049\/jimmunol.1103698","volume":"188","author":"ML Rio del","year":"2012","unstructured":"del Rio ML, Jones ND, Buhler L, Norris P, Shintani Y, Ware CF, Rodriguez-Barbosa JI (2012) Selective blockade of herpesvirus entry mediator-B and T lymphocyte attenuator pathway ameliorates acute graft-versus-host reaction. J Immunol 188(10):4885\u20134896","journal-title":"J Immunol"},{"issue":"4","key":"1815_CR36","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.molimm.2007.07.013","volume":"45","author":"ESK Rijkers","year":"2008","unstructured":"Rijkers ESK, de Ruiter T, Baridi A, Veninga H, Hoek RM, Meyaard L (2008) The inhibitory CD200R is differentially expressed on human and mouse T and B lymphocytes. Mol Immunol 45(4):1126\u20131135","journal-title":"Mol Immunol"},{"issue":"13","key":"1815_CR37","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1182\/blood-2006-06-029355","volume":"108","author":"J Moreaux","year":"2006","unstructured":"Moreaux J, Hose D, Reme T, Jourdan E, Hundemer M, Legouffe E, Moine P, Bourin P, Moos M, Corre J, M\u00f6hler T, De Vos J, Rossi JF, Goldschmidt H, Klein B (2006) CD200 is a new prognostic factor in multiple myeloma. Blood 108(13):4194\u20134197","journal-title":"Blood"},{"issue":"3","key":"1815_CR38","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/sj.leu.2404559","volume":"21","author":"A Tonks","year":"2007","unstructured":"Tonks A, Hills R, White P, Rosie B, Mills KI, Burnett AK, Darley RL (2007) CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 21(3):566\u2013568","journal-title":"Leukemia"},{"issue":"3","key":"1815_CR39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.exphem.2004.11.006","volume":"33","author":"A Romanski","year":"2005","unstructured":"Romanski A, Bug G, Becker S, Kampfmann M, Seifried E, Hoelzer D, Ottmann OG, Tonn T (2005) Mechanisms of resistance to natural killer cell-mediated cytotoxicity in acute lymphoblastic leukemia. Exp Hematol 33(3):344\u2013352","journal-title":"Exp Hematol"},{"issue":"4","key":"1815_CR40","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"SR Woo","year":"2012","unstructured":"Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tangsombatvisit S, Grosso JF, Netto G, Smeltzer MP, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 72(4):917\u2013927","journal-title":"Cancer Res"},{"key":"1815_CR41","doi-asserted-by":"crossref","unstructured":"Sanborn RE, Sharfman WH, Segal NH, Hodi FS, Wolchok JD, Urba WJ, Fox BA, Topalian SL, Pardoll DM, Covello K, McDonald D, Kim SY, Gupta A, Wigginton JM, Gajewski TF (2014) A phase I dose-escalation and cohort expansion study of lirilumab (anti-KIR; BMS-986015) administered in combination with nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced refractory solid tumors. J Clin Oncol 32 (suppl; abstr TPS3115)","DOI":"10.1200\/jco.2014.32.15_suppl.tps3115"},{"key":"1815_CR42","doi-asserted-by":"crossref","unstructured":"Rizvi NA, Infante JR, Gibney GT, Bertino EM, Cooley S, Lekatis K, Wigginton JM, Gutierrez AA, Gupta AK, Kim SY, Hodi FS (2013) A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal antibody, administered in combination with ipilimumab, an anti-CTLA4 monoclonal antibody, in patients (Pts) with select advanced solid tumors. J Clin Oncol 31 (suppl; abstr 3106)","DOI":"10.1200\/jco.2013.31.15_suppl.tps3106"},{"issue":"6","key":"1815_CR43","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-06-092817","volume":"112","author":"R Nishimura","year":"2008","unstructured":"Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, Karimi M, Negrin RS (2008) In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 112(6):2563\u20132574","journal-title":"Blood"},{"issue":"7","key":"1815_CR44","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","volume":"92","author":"M Introna","year":"2007","unstructured":"Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D\u2019Amico G, Biagi E, Parma M, Pogliani EM, Spinelli O, Baronciani D, Grassi A, Golay J, Barbui T, Biondi A, Rambaldi A (2007) Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 92(7):952\u2013959","journal-title":"Haematologica"},{"issue":"11","key":"1815_CR45","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bbmt.2011.05.012","volume":"17","author":"GG Laport","year":"2011","unstructured":"Laport GG, Sheehan K, Baker J, Armstrong R, Wong RM, Lowsky R, Johnston LJ, Shizuru JA, Miklos D, Arai S, Benjamin JE, Weng WK, Negrin RS (2011) Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 17(11):1679\u20131687","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"1815_CR46","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/14653240500499507","volume":"8","author":"RK Zhong","year":"2006","unstructured":"Zhong RK, Loken M, Lane TA, Ball ED (2006) CTLA-4 blockade by a human mAb enhances the capacity of AML-derived DC to induce T-cell responses against AML cells in an autologous culture system. Cytotherapy 8(1):3\u201312","journal-title":"Cytotherapy"},{"issue":"7","key":"1815_CR47","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3109\/14653249.2012.694419","volume":"14","author":"YC Linn","year":"2012","unstructured":"Linn YC, Yong HX, Niam M, Lim TJ, Chu S, Choong A, Chuah C, Goh YT, Hwang W, Loh Y, Ng HJ, Suck G, Chan M, Koh M (2012) A phase I\/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy 14(7):851\u2013859","journal-title":"Cytotherapy"},{"issue":"7","key":"1815_CR48","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bmt.2011.202","volume":"47","author":"YC Linn","year":"2012","unstructured":"Linn YC, Niam M, Chu S, Choong A, Yong HX, Heng KK, Hwang W, Loh Y, Goh YT, Suck G, Chan M, Koh M (2012) The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 47(7):957\u2013966","journal-title":"Bone Marrow Transplant"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1815-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-016-1815-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-016-1815-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T23:25:59Z","timestamp":1600298759000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-016-1815-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,10]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["1815"],"URL":"https:\/\/doi.org\/10.1007\/s00262-016-1815-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,10]]}}}